Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis
Authors' conclusion
Comorbid cancer was frequent in CKM participants and independently associated with worse outcomes, but it did not attenuate the treatment benefit of finerenone.
Study context
- Population
- Patients with cardio-kidney-metabolic (CKM) syndromepooled FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF
- Participants
- 18,991 patients
- Comparison
- Finerenone treatment effect by history of cancer vs no history of cancer
- History of cancern = 1,389
Methodological detailspooled participant-level analysis of FIDELIO-DKD, FIGARO-DKD and FINEARTS-HF
- Pooled participant-level analysis of FIDELIO-DKD, FIGARO-DKD and FINEARTS-HF
Primary result
As reported in the abstract
Finerenone effect on clinical outcomes by history of cancer (subgroup)
- Finerenone consistently reduced all-cause death, HF and all-cause hospitalization, a composite kidney outcome, MACE and new-onset AF, irrespective of history of cancer
Further findings
- Prevalence of cancer history — History of cancer
- 7.3%
- New cancer during follow-up (no prior cancer) · median follow-up 2.9 years
- 5.2% · 915 events
- Prevalence of cancer history: most commonly gastrointestinal, male reproductive, renal/urinary tract and haematologic cancers
All-cause mortality and all-cause hospitalization by history of cancer
- History of cancer associated with higher risks of all-cause mortality and all-cause hospitalization
Original publication
Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis. Eur Heart J. Published 18 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →